Same Virus, Different Medicine: How to Choose Between Acyclovir and Valacyclovir

When a physician writes a prescription for a herpes antiviral, two names appear on the list more frequently than any other: acyclovir and valacyclovir. Both medications share the same fundamental mechanism of action, and both carry decades of clinical evidence supporting their safety and effectiveness. Yet they are not interchangeable in every situation. Dosing schedules, absorption rates, cost structures, and patient-specific factors can all influence which drug is the better fit. This guide breaks down those differences so you can approach your next appointment with clarity.

What Is the Relationship Between These Two Drugs?

Valacyclovir is classified as a prodrug of acyclovir. That term — prodrug — means valacyclovir is an inactive compound that your body converts into acyclovir after you swallow it. The conversion happens rapidly in the intestinal wall and liver, where enzymes transform valacyclovir into its active form. Once that transformation is complete, both medications work identically: they inhibit viral DNA polymerase, an enzyme the herpes simplex virus needs to replicate.

In practical terms, this relationship means valacyclovir was engineered specifically to improve upon acyclovir's limitations — particularly its absorption profile. Understanding that distinction is the starting point for comparing the two.

Bioavailability: The Absorption Advantage

One of the most clinically significant differences between these two antivirals is bioavailability, which refers to the proportion of a drug that actually enters your bloodstream and becomes available to fight the virus.

Oral acyclovir has a bioavailability of approximately 10 to 20 percent. That figure is relatively low, which is one reason acyclovir tablets must be taken multiple times per day — the body can only absorb a limited amount at each dose. Valacyclovir, by contrast, achieves bioavailability of roughly 54 percent after conversion to acyclovir. This means a smaller number of doses can deliver equivalent or greater antiviral exposure in the body.

For patients managing herpes outbreaks or suppressive therapy over the long term, this pharmacokinetic advantage translates directly into fewer daily pills.

Dosing Schedules: Frequency and Convenience

The difference in bioavailability has a direct effect on how often each medication must be taken.

Acyclovir for a genital herpes outbreak is typically prescribed at 400 mg three times daily, or 200 mg five times daily, for five days. For suppressive therapy — taken daily to reduce the frequency of outbreaks — the standard dose is 400 mg twice daily. Cold sore treatment with acyclovir requires five daily doses.

Valacyclovir simplifies these schedules considerably. A genital herpes outbreak is generally treated with 500 mg or 1,000 mg twice daily for three to five days. Suppressive therapy requires just 500 mg to 1,000 mg once daily. Cold sores can often be addressed with a single-day, high-dose regimen.

For individuals with demanding schedules, those who travel frequently, or patients managing multiple medications, fewer daily doses can meaningfully improve adherence. Missed doses reduce antiviral effectiveness, so convenience is not merely a comfort issue — it has real clinical relevance.

Cost Considerations in the United States

Generic versions of both medications are widely available in the United States, and both are relatively affordable by prescription drug standards. However, acyclovir is generally the less expensive of the two.

At most major US pharmacies, a month's supply of generic acyclovir for suppressive therapy can cost between $15 and $40 without insurance, depending on the pharmacy and the dose. Generic valacyclovir is typically priced somewhat higher, though prices vary considerably by location and pharmacy benefit plan.

For patients without prescription drug coverage, or those enrolled in high-deductible health plans, the cost differential may make acyclovir the practical choice. Pharmacy discount programs such as GoodRx and similar platforms can reduce out-of-pocket costs for both drugs, and it is worth comparing prices at multiple pharmacies before filling a new prescription.

Who Benefits Most From Acyclovir?

Acyclovir remains an excellent first-line antiviral for many patients. It is particularly well-suited for:

• Individuals managing occasional outbreaks who do not require the convenience of once-daily dosing
• Cost-sensitive patients for whom the lower price of acyclovir is a meaningful consideration
• Children and immunocompromised individuals in whom acyclovir has the longest safety record and the most established dosing guidelines
• Patients with herpes zoster (shingles) who are prescribed higher doses, where acyclovir has extensive documented use
• Those requiring intravenous antiviral therapy, since IV acyclovir remains the standard of care for severe herpes infections, including herpes encephalitis

Acyclovir is also available in topical formulations for oral herpes, though topical antivirals generally offer more modest benefits compared to systemic (oral or IV) treatment.

Who Benefits Most From Valacyclovir?

Valacyclovir's improved bioavailability and simplified dosing make it the preferred choice in several clinical scenarios:

• Patients on long-term suppressive therapy who benefit from once-daily dosing to support consistent adherence
• Individuals with frequent or severe outbreaks where higher sustained blood levels of acyclovir may provide better viral suppression
• Those concerned about transmission to a partner, as clinical trials have shown valacyclovir reduces the risk of herpes transmission to uninfected sexual partners when used as suppressive therapy
• Patients who find multiple daily doses difficult to manage due to work schedules, travel, or pill fatigue
• Cold sore sufferers seeking rapid resolution, where the single-day valacyclovir regimen has shown efficacy in clinical studies

Special Populations and Safety Considerations

Both medications require dose adjustments for patients with impaired kidney function, as acyclovir is primarily excreted through the kidneys. Your healthcare provider will assess your renal function before establishing a dosing regimen. Adequate hydration is also important with both drugs to reduce the risk of crystalluria, a condition in which drug crystals form in the urine.

Pregnant patients should discuss antiviral use with their obstetrician. Both acyclovir and valacyclovir have been used during pregnancy, and existing data do not indicate significant fetal risk, but individualized medical guidance is essential.

Making the Decision With Your Doctor

Neither medication is universally superior. The right choice depends on your specific diagnosis, outbreak frequency, kidney health, daily routine, and financial situation. A prescribing physician or pharmacist can help weigh these factors and tailor a treatment plan accordingly.

What matters most is that antiviral therapy is initiated promptly when indicated. Whether the prescription reads acyclovir or valacyclovir, beginning treatment early — ideally at the first sign of an outbreak — produces the best clinical outcomes. The differences between these two medications are meaningful, but they are differences in delivery, not in the fundamental commitment to managing herpes effectively and safely.